Publications by authors named "L Petitjean"
Metabolic dysfunction-associated steatohepatitis (MASH) is a severe liver disease characterized by lipid accumulation, inflammation and fibrosis. The development of MASH therapies has been hindered by the lack of human translational models and limitations of analysis techniques for fibrosis. The MASH three-dimensional (3D) InSight™ human liver microtissue (hLiMT) model recapitulates pathophysiological features of the disease.
View Article and Find Full Text PDFUnlabelled: Melanoma is the leading cause of skin cancer-related death. As prognosis of patients with melanoma remains problematic, identification of new therapeutic targets remains essential. Matricellular proteins are nonstructural extracellular matrix proteins.
View Article and Find Full Text PDFBackground & Aims: Digital pathology image analysis can phenotype liver fibrosis using histological traits that reflect collagen content, morphometry and architecture. Here, we aimed to calculate fibrosis severity scores to quantify these traits.
Methods: Liver biopsy slides were categorised by Ishak stage and aetiology.
Article Synopsis
- Semaglutide is an antidiabetic drug recently approved for obesity treatment and shows promise for non-alcoholic steatohepatitis (NASH) therapy.
- In an experiment with Ldlr-/-.Leiden mice on a high-fat diet, semaglutide significantly reduced liver fat and inflammation, but did not significantly affect fibrosis.
- The study suggests semaglutide is effective for addressing liver fat and inflammation in NASH, although additional treatments may be required for advanced fibrosis.
Article Synopsis
- - The study measured protein levels in 986 individuals to predict the severity of COVID-19, using both protein data and clinical risk factors to build predictive models.
- - A baseline model using age and sex achieved a prediction accuracy of 65%, but incorporating 92 specific proteins improved this accuracy to 88% in the initial group and maintained 86% in a separate test group.
- - Findings indicate that early-stage protein measurements can effectively predict COVID-19 severity, highlighting the need for further research to integrate these measurements into clinical practice.